Tag - LUCD

Developments

Lucid reports positive data from ESOGUARD BE-1 study in BE and EAC patients

Lucid Diagnostics (NASDAQ:LUCD) announced positive results from its clinical validation study of EsoGuard Esophageal DNA test on samples collected from patients with Barrett’s Esophagus (BE) and esophageal...

July 5, 2024

Markets

Analysts start Lucid Diagnostics at buy: PTs $14, $18

Analysts for BTIG and Canaccord Genuity launched coverage of Lucid Diagnostics (NASDAQ:LUCD) with “buy” ratings and price targets of $14 and $18, respectively. The stock closed at $9.52 on Oct. 5. Lucid recently...

November 8, 2021

Tag - LUCD

Lucid reports positive data from ESOGUARD BE-1 study in BE and EAC patients

Analysts start Lucid Diagnostics at buy: PTs $14, $18

General

More